BioSpace News Archive

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, announced today that Heather Brennan has joined the company as Head of U.S. Commercial Operations and Neeta Toprani has joined as General Counsel & Corporate Secretary.

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) ( TSXV: MDP , OTCQX: MEDXF ), today announced that management will present at the LD Micro Invitational XI investor conference taking place virtually June 8-10, 2021.

Auris Medical Holding Ltd., a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergology, announced that its affiliate Altamira Medica Ltd. has started preparations for the conduct of a study with its BentrioTM nasal spray for protection against airborne viruses and allergens in India.

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in several industry and investor events: NCVH Annual Conference (June 1-4, 2021)

Equita Group S.p.A., a leading Italian based investment bank, advising Dragon SPAC; Cantor Fitzgerald & Co. advising Jaguar on non-deal related activities

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a question-and-answer session at the 42nd annual Goldman Sachs Healthcare Conference on June 9. Dr. Countouriotis’ session is scheduled to begin at 1:20 p.m. ET and will be accessible via audio webcast

The Red Cross and American Cancer Society kick off partnership as the need for lifesaving platelet donations intensifies during emergency shortage

Alkermes plc announced that the U.S. Food and Drug Administration has approved LYBALVI™ for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate.

Experienced technical operations and CMC leader brings scientific and strategic expertise in oncology drug development and life cycle management

APOLLO-B is the Industry’s Furthest Progressed Randomized, Double-Blind, Placebo-Controlled Pivotal Study of an Investigational TTR Silencer in Hereditary and Wild-type ATTR Amyloidosis with Cardiomyopathy